DataMeds AI, Inc MEDS
3.11
(0.39)
(11.14%)
as of 25 Sep
- Market cap
- $10.9M
- P/E
- 0.0×
Follow MEDS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+7 more quarters Free account |
P/S ratio |
0.99 | 0.72 | 1.22 | 1.94 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.76) | (2.94) | (4.51) | (58.11) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 9.73 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.14 | 2.22 | 2.22 | 2.66 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.84) | (2.41) | (4.78) | (12.61) | |
EV/FCF |
(1.72) | (2.27) | (4.42) | (12.00) | |
Quick Ratio |
0.09 | 0.03 | 0.04 | 0.16 | |
Current Ratio |
0.14 | 0.09 | 0.09 | 0.39 | |
Net Debt/EBITDA |
(2.81) | (5.07) | (1.89) | (0.81) | |
Debt/Assets |
60.15% | 70.38% | 77.11% | 54.62% | |
Debt/Equity |
(1.01) | (1.41) | (1.89) | 4.25 | |
Asset Turnover |
0.18 | 0.32 | 0.53 | 1.29 | |
Operating CF/Net income |
0.16 | 0.44 | 0.23 | 0.03 | |
Capex/Depreciation |
(0.20) | (0.11) | (0.02) | (0.18) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
402.87% | 373.74% | 247.76% | 1,028.13% | |
Intangible Assets out of Total Assets |
0.73 | 0.80 | 0.80 | 0.66 | |
Share Based Compensation of Revenue |
67.68% | 87.06% | 21.29% | 854.00% | |
Graham Net Nets |
(5.84) | (4.22) | (1.41) | (0.50) | |
Graham Number |
88.67 | 84.90 | 119.18 | 0.00 | |
Earnings Yield |
(1,488.06%) | (927.08%) | (360.00%) | (144.55%) | |
Free Cash Flow Yield |
(183.67%) | (136.75%) | (41.33%) | (11.44%) | |
Revenue per Share |
0.69 | 0.75 | 1.18 | 2.03 | |
Operating CF per Share |
(1.12) | (1.63) | (4.43) | (0.76) | |
Capex per Share |
(0.09) | (0.10) | (0.18) | (0.15) | |
Free Cash Flow per Share |
(1.22) | (1.73) | (4.61) | (0.91) | |
Cash per Share |
0.95 | 0.02 | 0.03 | 2.84 | |
Shareholders Equity per Share |
(7.58) | (7.20) | (8.77) | 4.56 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(7.58) | (7.20) | (8.77) | 4.56 | |
Free Cash Flow |
(3.14) | (3.62) | (6.55) | (1.36) | |
Working Capital |
(33.78) | (29.44) | (26.96) | (19.92) | |
Capital Expenditures |
(0.24) | (0.21) | (0.26) | (0.22) | |
Net Current Asset Value |
(46.63) | (42.43) | (40.09) | (33.18) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.14 | 0.13 | 0.15 | 0.07 | |
Net Profit Margin |
(1,031.70%) | (496.45%) | (1,667.15%) | (1,139.04%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.60 | 2.48 | 2.44 | 0.72 | |
Average Payables |
11.06 | 10.11 | 9.01 | 5.74 | |
Average Inventory |
5.27 | 5.72 | 5.58 | — | |
Average Assets |
43.49 | 44.10 | 43.90 | 26.39 | |
Average Common Equity |
(9.30) | (5.29) | (2.86) | 1.94 |
Columns are period end dates